Question: It is December 2022. You work as a financial analyst for Merck & Co. and are tasked with the due diligence on the proposed acquisition
It is December 2022. You work as a financial analyst for Merck & Co. and are tasked with the due diligence on the proposed acquisition of a biotech startup. You estimated the following cash flows for the startup:
| Year | Expected free cash flow ($ million) (end of year) |
| 2023 | 86.5 |
| 2024 | 129.75 |
| 2025 | 168.68 |
| 2026 | 202.41 |
| 2027 | 222.65 |
After 2027, cash flows are expected to grow by 3% per year. Based on the riskiness of your industry, you think that your weighted average cost of capital is 17%.
The biotech firm has 5 million shares and bonds worth $120 million outstanding.
Part 1
What is the terminal value, i.e., the present value of all free cash flows from 2028 to infinity expressed in 2027-dollars (in $ million)?
Part 2
What is the total value of the company (in $ million)?
Part 3
What is the value per share of common stock (in $)?
Step by Step Solution
There are 3 Steps involved in it
Get step-by-step solutions from verified subject matter experts
